Methods of gene therapy using herpes viral vectors expressing GM-CSF
US6287557A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Feb 21, 1996 |
| Grant date | Sep 11, 2001 |
| Priority date | — |
| Expiry date | Feb 21, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/16662
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A genetically disabled mutant virus has a genome which is defective in respect of a selected gene that is essential for the production of infectious new virus particles, and which carries heterologous genetic material encoding an immunomodulatory protein such as GM-CSF, IL-2, or others, such that the mutant virus can infect normal host cells and cause expression of immunomodulatory protein, but the mutant virus cannot cause production of infectious new virus particles except when the virus infects recombinant complementing host cells expressing a gene that provides the function of the essential viral gene; the site of insertion of the heterologous genetic material encoding the immunomodulatory protein preferably being at the site of the defect in the selected essential viral gene. Uses include prophylactic and therapeutic use in generating an immune response in a subject treated therewith; use in the preparation of an immunogen such as a vaccine for use in tumor therapy; use in the in-vitro expansion of (e.g. virus-specific) cytotoxic T cells; and therapeutic or prophylactic use in corrective gene therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.